← ANALYST RATINGS · TIPRANKS
Q32 Bio (QTTB): analyst forecast and price target
Analyst consensus
Strong Buy5 Buy0 Hold0 Sell
Ratings of 5 analysts in the last 3 months · top analysts only12-month forecast
Based on 5 price targets given in the last 3 months, the average target is $40.40, the highest $59.00, the lowest $29.00. The average is +437.2% from the last price of $7.52.
| Analyst | Firm | Price target | Rating | Upside | Action | Date | Move vs SPY | |
|---|---|---|---|---|---|---|---|---|
| Unknown Analyst | Leerink Partners | $40.00 | Buy | +431.9% | Initiated | 12.10.26on TipRanks Oct 16 21:02 | +4.9%next day −7.8% | ↗ |
| Maury Raycroft★★★★★★★★★★#1326 · hits 44% · avg +12.0% | Jefferies | $29.00 | Buy | +285.6% | Reiterated | 01.10.26on TipRanks 10:25 | −0.4%next day −1.0% · 5 days −3.2% | ↗ |
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $11.00 → $9.50−13.6% | Buy | +26.3% | Reiterated | 01.10.26on TipRanks 03:05 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $10.50 → $9.00−14.3% | Buy | +19.7% | Reiterated | 01.10.26on TipRanks 03:05 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $10.00 → $8.50−15.0% | Hold | +13.0% | Reiterated | 01.10.26on TipRanks 03:05 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $9.50 → $8.00−15.8% | Hold | +6.4% | Reiterated | 01.10.26on TipRanks 03:05 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $10.50 → $9.50−9.5% | Buy | +26.3% | Reiterated | 01.10.26on TipRanks 03:05 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $10.50 → $9.00−14.3% | Hold | +19.7% | Reiterated | 01.10.26on TipRanks 03:05 | — | |
| Derek Archila★★★★★★★★★★#252 · hits 58% · avg +22.7% | Wells Fargo | $59.00 | Buy | +684.6% | Reiterated | 30.09.26on TipRanks Oct 1 05:30 | −13.0%next day −0.4% · 5 days −5.3% | ↗ |
| Joseph Pantginis★★★★★★★★★★#243 · hits 55% · avg +24.8% | H.C. Wainwright | $36.00 | Buy | +378.7% | Reiterated | 30.09.26on TipRanks 13:15 | −13.0%next day −0.4% · 5 days −5.3% | ↗ |
| Kaveri Pohlman★★★★★★★★★★#1640 · hits 40% · avg +12.9% | Clear Street | $38.00 | Buy | +405.3% | Initiated | 29.09.26on TipRanks Sep 28 16:45 | +3.4%next day −13.0% · 5 days −16.8% | ↗ |
| Judah Frommer★★★★★★★★★★#2495 · hits 56% · avg +5.3% | Morgan Stanley | $34.00 | Buy | +352.1% | Initiated | 24.08.26on TipRanks 05:15 | +2.7%next day −0.6% · 5 days −9.6% | ↗ |
| Jay Olson★★★★★★★★★★#301 · hits 48% · avg +24.9% | Oppenheimer | $40.00 | Buy | +431.9% | Reiterated | 06.08.26on TipRanks 09:01 | −1.6%next day −4.3% · 5 days −6.3% | ↗ |
| Joseph Catanzaro★★★★★★★★★★#981 · hits 46% · avg +13.3% | Mizuho Securities | $14.00 → $36.00+157.1% | Buy | +378.7% | Reiterated | 13.07.26on TipRanks 14:20 | +91.5%next day −14.0% · 5 days −28.7% | ↗ |
| Imogen Mansfield★★★★★★★★★★#4639 · hits 57% · avg +23.8% | Cantor Fitzgerald | — | Buy | — | Initiated | 18.05.26on TipRanks May 19 00:05 | −8.7%next day +6.2% · 5 days +21.7% | ↗ |
| No ratings for this filter. | ||||||||
The latest rating of each analyst in the last 12 months, as TipRanks lists them. Every rating kept, earlier ones included
Best analysts covering Q32 Bio
TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.
Most accurate
Most profitable
How the average price target moved
The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 01.10.26: target $38.86 at a price of $8.27 (+369.9%); now: $39.43 at $7.52 (+424.3%).
PriceAverage targetTop analysts’ target
Recommendation trend · top analysts
Strong BuyBuyHoldSell
| Rating | 05.26 | 06.26 | 07.26 | 08.26 | 09.26 | 10.26 |
|---|---|---|---|---|---|---|
| Strong Buy | 5 | 3 | 6 | 7 | 9 | 7 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 2 | 1 | 1 | 0 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Earnings and sales forecast
Next report: 05.11.26 (Q3 2026, date not confirmed)
Earnings per share
Next quarter’s EPS estimate — $-0.33 (from $-0.42 to $-0.27). Last quarter: $-0.44.
Best top-analyst consensus in the sector · Healthcare
About Q32 Bio
- CEO: Jodie Pope Morrison
- Employees: 22
- 830 Winter Street, Waltham, MA, 02451, US
- www.q32bio.com
Operating as a clinical-stage biotechnology firm, Q32 Bio Inc. is dedicated to developing biologic therapies aimed at re-establishing healthy immune equilibrium in patients across the United States suffering from autoimmune and inflammatory disorders stemming from dysfunctional immune responses. The company's primary investigational therapy, ADX-097, is a humanized anti-C3d monoclonal antibody fusion protein designed to normalize complement regulation. This candidate has successfully finished its Phase I clinical trial, targeting severe renal and other complement-driven conditions where patient needs are largely unmet, such as lupus nephritis, IgA nephropathy, C3 glomerulopathy, and ANCA-associated vasculitis. Additionally, Q32 Bio is advancing Bempikibart (ADX-914), a fully human monoclonal antibody antagonist against interleukin-7 receptor alpha. Currently in Phase II trials, Bempikibart aims to recalibrate adaptive immune responses by inhibiting signaling pathways involving interleukin-7 and thymic stromal lymphopoietin, offering potential treatment for atopic dermatitis and alopecia areata. Founded in 2017 and headquartered in Waltham, Massachusetts, Q32 Bio Inc. adopted its current name in April 2020, having previously operated as AdMIRx Inc.
Data from the stock’s TipRanks forecast page, read 1 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗